Why the study?
Do therapies targeting triglycerides and HDL-cholesterol reduce cardiovascular risk in patients with or at risk for CHD?
Population
Patients with or at risk for coronary heart disease (CHD)
Design
Review
Authors
Loading...
Prioritizes LDL-C lowering in dyslipidemia management; leaves open whether TG- or HDL-targeted therapies reduce cardiovascular risk.
Do therapies targeting triglycerides and HDL-cholesterol reduce cardiovascular risk in patients with or at risk for CHD?
While low HDL-C and high triglycerides are risk factors for CHD, current guidelines prioritize LDL-C lowering and consider evidence insufficient for specific HDL-C targets.
Fruchart et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: